Sarepta Therapeutics Inc (NASDAQ: SRPT)’s stock price has dropped by -9.36 in relation to previous closing price of 70.41. Nevertheless, the company has seen a loss of -16.39% in its stock price over the last five trading days. businesswire.com reported 2025-03-31 that CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 31, 2025 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 39 individuals hired by Sarepta in the first quarter of 2025. The equity awards were approved in accordance with Nasdaq Listing Rule.
Is It Worth Investing in Sarepta Therapeutics Inc (NASDAQ: SRPT) Right Now?
The price-to-earnings ratio for Sarepta Therapeutics Inc (NASDAQ: SRPT) is above average at 26.78x. The 36-month beta value for SRPT is also noteworthy at 0.90. There are mixed opinions on the stock, with 12 analysts rating it as a “buy,” 9 rating it as “overweight,” 2 rating it as “hold,” and 1 rating it as “sell.”
The public float for SRPT is 91.14M, and at present, short sellers hold a 5.33% of that float. The average trading volume of SRPT on April 01, 2025 was 1.28M shares.
SRPT’s Market Performance
SRPT’s stock has seen a -16.39% decrease for the week, with a -40.22% drop in the past month and a -48.27% fall in the past quarter. The volatility ratio for the week is 5.11%, and the volatility levels for the past 30 days are at 5.04% for Sarepta Therapeutics Inc The simple moving average for the last 20 days is -26.90% for SRPT’s stock, with a simple moving average of -48.30% for the last 200 days.
Analysts’ Opinion of SRPT
Deutsche Bank, on the other hand, stated in their research note that they expect to see SRPT reach a price target of $136. The rating they have provided for SRPT stocks is “Hold” according to the report published on February 11th, 2025.
Needham gave a rating of “Buy” to SRPT, setting the target price at $202 in the report published on November 27th of the previous year.
SRPT Trading at -37.29% from the 50-Day Moving Average
After a stumble in the market that brought SRPT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.16% of loss for the given period.
Volatility was left at 5.04%, however, over the last 30 days, the volatility rate increased by 5.11%, as shares sank -36.95% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -45.48% lower at present.
During the last 5 trading sessions, SRPT fell by -16.39%, which changed the moving average for the period of 200-days by -47.42% in comparison to the 20-day moving average, which settled at $87.31. In addition, Sarepta Therapeutics Inc saw -47.51% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SRPT starting from Nicaise Claude, who sale 2,491 shares at the price of $99.64 back on Mar 12 ’25. After this action, Nicaise Claude now owns 27,812 shares of Sarepta Therapeutics Inc, valued at $248,203 using the latest closing price.
Nicaise Claude, the Director of Sarepta Therapeutics Inc, proposed sale 2,491 shares at $99.65 during a trade that took place back on Mar 12 ’25, which means that Nicaise Claude is holding shares at $248,226 based on the most recent closing price.
Stock Fundamentals for SRPT
Current profitability levels for the company are sitting at:
- 0.11 for the present operating margin
- 0.83 for the gross margin
The net margin for Sarepta Therapeutics Inc stands at 0.12. The total capital return value is set at 0.07. Equity return is now at value 19.71, with 6.51 for asset returns.
Based on Sarepta Therapeutics Inc (SRPT), the company’s capital structure generated 0.47 points at debt to capital in total, while cash flow to debt ratio is standing at -0.15. The debt to equity ratio resting at 0.87. The interest coverage ratio of the stock is 11.86.
Currently, EBITDA for the company is 316.89 million with net debt to EBITDA at 0.74. When we switch over and look at the enterprise to sales, we see a ratio of 3.37. The receivables turnover for the company is 2.93for trailing twelve months and the total asset turnover is 0.48. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.20.
Conclusion
In summary, Sarepta Therapeutics Inc (SRPT) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
